HHS In role
Bret Koplow
Director, FDA Center for Tobacco Products (CTP)
Director of the FDA's Center for Tobacco Products since September 2026, after a year as its acting director. An FDA lawyer since 2011 — and before that a clinical psychologist who ran child and adolescent psychiatry divisions — Koplow has made tobacco harm reduction and clearing the premarket application backlog the center's stated mission.
Role status — October 2026: Koplow is the permanent director of the Center for Tobacco Products, appointed in September 2026 (announced September 8 as part of an HHS leadership package) after joining CTP as acting director in 2025. CTP is the FDA center that carries out the 2009 Tobacco Control Act — regulating the manufacture, distribution, and marketing of tobacco products and deciding which new products may be lawfully sold.
Koplow is a career FDA official with an unusual double background. He joined the agency in 2011 after practicing food and drug law as a partner at Washington law firms, then rotated through the Office of Legislation, the Office of the Chief Counsel, and — from early 2020 — the Commissioner’s immediate office as Senior Counselor to the Commissioner, working principally on matters headed to CTP. Before law school (J.D. with honors, University of Chicago), he earned a Ph.D. in clinical psychology and directed the Divisions of Child and Adolescent Psychiatry at Case Western Reserve School of Medicine and University Hospitals of Cleveland — experience he cites when he talks about early nicotine exposure.
His tenure so far is defined by two pushes. The first is throughput: in a May 2026 statement he reported that CTP cut the backlog of premarket tobacco product applications by roughly 70 percent in 2025 and eliminated the queue for acceptance review. The second is doctrine: in his first FDLI keynote as permanent director he called tobacco harm reduction the core of FDA’s vision, described the statutory “appropriate for the protection of public health” standard as itself a harm-reduction standard, and pointed to the nicotine pouch pilot program’s 23 authorizations as a model — while conceding that some 5,300 substantial equivalence reports remain pending. That framing puts him at the center of the fight over flavored vapes, nicotine pouches, and the illicit import market.
Why tracked here: Koplow decides which nicotine products Americans may legally buy — and his harm-reduction framing is the administration’s clearest statement of where tobacco regulation goes next.
Sources (Oct 2026): FDA leadership biography; RAPS, Sept. 8, 2026; STAT, Sept. 8, 2026; FDA CTP statement, May 7, 2026; Cigar Rights of America FDLI 2026 report; Tobacco Reporter, Sept. 14, 2026.